Please wait
S-8 S-8 EX-FILING FEES 0001551152 AbbVie Inc. Fees to be Paid Fees to be Paid 0001551152 2024-10-31 2024-10-31 0001551152 1 2024-10-31 2024-10-31 0001551152 2 2024-10-31 2024-10-31 iso4217:USD xbrli:pure xbrli:shares

Calculation of Filing Fee Tables

S-8

AbbVie Inc.

Table 1: Newly Registered Securities

Security Type

Security Class Title

Fee Calculation Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

1 Other Deferred Compensation Obligations Other $ 275,000,000.00 0.0001531 $ 42,102.50
2 Other Deferred Compensation Obligations Other $ 75,000,000.00 0.0001531 $ 11,482.50

Total Offering Amounts:

$ 350,000,000.00

$ 53,585.00

Total Fee Offsets:

$ 0.00

Net Fee Due:

$ 53,585.00

Offering Note

1

The deferred compensation obligations are unsecured obligations of AbbVie Inc. (the "Registrant") to pay deferred compensation in the future pursuant to the terms of the AbbVie Deferred Compensation Plan (the "DCP"). The maximum aggregate offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act of 1933, as amended (the "Securities Act"), based upon an estimate of the amount of compensation participants may defer under the DCP.

2

The deferred compensation obligations are unsecured obligations of the Registrant to pay deferred compensation in the future pursuant to the terms of the AbbVie Deferred Compensation Plan Plus (the "DCP Plus"). The maximum aggregate offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) of the Securities Act, based upon an estimate of the amount of compensation participants may defer under the DCP Plus.